Investment Rating - The report maintains an "Accumulate" rating for the company [1][10] Core Insights - The company reported a significant year-on-year revenue growth of 34.05% for the first three quarters of 2025, reaching 503 million yuan, with a net profit increase of 86.57% to 46 million yuan [1][3] - The revenue breakdown shows that the semiconductor sector contributed 58.80% of total revenue, followed by life sciences and medical at 18.24%, and AR/VR testing at 9.28% [3] - The gross margin for the first three quarters of 2025 was 47.75%, a slight decrease of 0.40 percentage points year-on-year, while the net margin improved by 2.56 percentage points to 9.08% [4] Financial Performance - For Q3 2025, the company achieved a revenue of 184 million yuan, reflecting a year-on-year growth of 37.27% and a quarter-on-quarter increase of 4.24% [3] - The net profit for Q3 2025 was 13 million yuan, up 45.03% year-on-year, although it saw a decline of 19.73% quarter-on-quarter [3] - The company’s gross margin for Q3 2025 was 44.46%, down 4.55 percentage points year-on-year and 4.53 percentage points quarter-on-quarter [4] Earnings Forecast - The company is projected to achieve revenues of 673 million yuan, 871 million yuan, and 1.07 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 63 million yuan, 97 million yuan, and 139 million yuan [4][10] - The price-to-earnings (P/E) ratios for the years 2025, 2026, and 2027 are estimated to be 293, 192, and 134 respectively [4][10]